The FDA has approved Pfizer’s adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira.
The FDA has approved Pfizer’s adalimumab biosimilar, Abrilada (adalimumab-afzb), referencing Humira.
In a statement, Sarah Yim, MD, acting director of the FDA’s Office of Therapeutic Biologics and Biosimilars in the Center for Drug Evaluation and Research, said she is pleased to see the 25th biosimilar approved in the United States, and that she is confident that the market for these products will continue to grow.
The biosimilar was studied in a 78-week, double-blind, multicenter, randomized study comparing the proposed biosimilar with EU-licensed Humira in 597 biologic-naïve patients with rheumatoid arthritis, and 26-week results of the study have been published.1
The study’s primary end point was the proportion of patients reaching the American College of Rheumatology’s criteria for 20% improvement (ACR20) at week 12, which the investigators say is a sensitive timepoint for assessment of the speed of response, as it represents the start of the plateau of the time-response curve for ACR20.
The 26-week period of initial treatment was completed by 286 patients in the biosimilar arm and 273 patients in the reference arm. In the biosimilar arm, 68.7% of patients achieved ACR20, as did 72.7% of patients in the reference arm; the treatment difference was −3.98%, which was contained within the prespecified equivalence margin of ±14%. ACR20, 50, and 70 rates were also similar through week 26 for both groups.
Despite the new FDA approval, Abrilada will not be free to launch in the US market until November 20, 2023, after Pfizer struck an agreement with Humira’s maker, AbbVie, to end patent litigation in 2018.
Abrilada joins multiple other approved but unlaunched biosimilar adalimumab products in the United States; also permitted to launch in 2023 on the basis of patent settlements are Hyrimoz (developed by Sandoz), Cyltezo (Boehringer Ingelheim), Hadlima (Samsung Bioepis), and Amjevita (Amgen).
Reference
1. Fleischmann RM, Alten R, Pileckyte M, et al. A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira) in the treatment of active rheumatoid arthritis. Arthritis Res Ther. 2018;20(1):178. doi: 10.1186/s13075-018-1676-y.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.